Disease · MONDO_0005233
Comparisons in its trials902
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 902
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Biomarker Cohort vs Non-biomarker Cohort: deaths from any cause | 364 of 618 | 3,780 of 4,661 | 5,279 | NCT05834348 | Trial comparisons |
| Darbepoetin Alfa vs Placebo: deaths from any cause | 1,273 of 1,685 | 657 of 833 | 2,518 | NCT00858364 | Trial comparisons |
| Darbepoetin Alfa vs Placebo: serious adverse events | 524 of 1,685 | 259 of 833 | 2,518 | NCT00858364 | Trial comparisons |
| Darbepoetin Alfa vs Placebo: Number of Participants Who Developed Neutralizing Antibodies to Darbepoetin Alfa | 0 of 1,606 | 0 of 803 | 2,409 | NCT00858364 | Trial comparisons |
| GSK1572932 Group vs Placebo Group: Number of Patients With Serious Adverse Events (SAEs) - Up to Data Lock Point (DLP) | 330 of 1,515 | 164 of 757 | 2,272 | NCT00480025 | Trial comparisons |
| GSK1572932 Group vs Placebo Group: deaths from any cause | 30 of 1,515 | 17 of 757 | 2,272 | NCT00480025 | Trial comparisons |
| GSK1572932 Group vs Placebo Group: serious adverse events | 330 of 1,515 | 164 of 757 | 2,272 | NCT00480025 | Trial comparisons |
| Tecemotide (L-BLP25) + Cyclophosphamide vs Saline + Placebo: serious adverse events | 303 of 1,024 | 151 of 477 | 1,501 | NCT00409188 | Trial comparisons |
| Arm I (Chemotherapy) vs Arm II (Chemotherapy, Bevacizumab): serious adverse events | 424 of 738 | 563 of 735 | 1,473 | NCT00324805 | Trial comparisons |
| Vandetanib 100 mg Plus Docetaxel vs Placebo Plus Docetaxel: Objective Response Rate (ORR) | 120 of 694 | 71 of 697 | 1,391 | NCT00312377 | Trial comparisons |
| Vandetanib 100 mg Plus Docetaxel vs Placebo Plus Docetaxel: Disease Control Rate (DCR) | 413 of 694 | 380 of 697 | 1,391 | NCT00312377 | Trial comparisons |
| Vandetanib 100 mg Plus Docetaxel vs Placebo Plus Docetaxel: serious adverse events | 263 of 694 | 232 of 697 | 1,391 | NCT00312377 | Trial comparisons |
| Arm I (Chemo +/- Bevacizumab) vs Arm II (Chemo, Cetuximab, +/- Bevacizumab): deaths from any cause | 593 of 657 | 570 of 656 | 1,313 | NCT00946712 | Trial comparisons |
| Nintedanib Plus Docetaxel vs Placebo Plus Docetaxel: deaths from any cause | 107 of 652 | 77 of 655 | 1,307 | NCT00805194 | Trial comparisons |
| Nintedanib Plus Docetaxel vs Placebo Plus Docetaxel: serious adverse events | 224 of 652 | 206 of 655 | 1,307 | NCT00805194 | Trial comparisons |
| Arm I (Chemo +/- Bevacizumab) vs Arm II (Chemo, Cetuximab, +/- Bevacizumab): serious adverse events | 66 of 632 | 97 of 627 | 1,259 | NCT00946712 | Trial comparisons |
| Pembrolizumab vs Chemotherapy (SOC Treatment): Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE) | 126 of 636 | 93 of 615 | 1,251 | NCT02220894 | Trial comparisons |
| Pembrolizumab vs Chemotherapy (SOC Treatment): Number of Participants Who Experienced At Least One Adverse Event (AE) | 608 of 636 | 606 of 615 | 1,251 | NCT02220894 | Trial comparisons |
| Ramucirumab and Docetaxel vs Placebo and Docetaxel: serious adverse events | 284 of 627 | 281 of 618 | 1,245 | NCT01168973 | Trial comparisons |
| Vandetanib vs Erlotinib: Objective Response Rate (ORR) | 75 of 623 | 74 of 617 | 1,240 | NCT00364351 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005233/comparisons